A microbroth dilution method was used to measure the MICs of cefpiramide (SM 1652), cefotaxime, moxalactam, ceftazidime, cefoperazone, ceftriaxone, piperacillin, and mezlocillin against 921 isolates of gram-negative (701) and gram-positive (220) bacteria. The activity of cefpiramide was equivalent to those of piperacillin and mezlocillin against members of the family Enterobacteriaceae and gram-positive isolates, including enterococci. Cefpiramide had equivalent or slightly greater activity against Pseudomonas aeruginosa than the other ,B-lactam antibiotics tested.
Cefpiramide (SM 1652) is a new semisynthetic cephalosporin that was developed by Sumitomo Chemical Co., Ltd., Tokyo, Japan, and is currently manufactured in the United States by Wyeth Laboratories, Philadelphia, Pa. Recently, two large Japanese studies have compared the in vitro activity of cefpiramnide with those of several of the new cephalosporins, including cefoperazone, cefotaxime, cefazolin, cefsulodin, and cefmnetazole (1, 3) . These studies reported that the antibacterial activity of cefpiramide compared favorably with those of the other cephalosporins and that it was considerably rnore potent against Pseudomonas aeruginosa isolates. In addition, the compound has favorable pharmacokinetic properties in humans, with a half-life of 5 h in plasma and a maximum concentration of 303 ,ug/ml in serum after administration of a 1-g bolus dose to healthy volunteers (data on file, Wyeth Laboratories). On the basis of these promising reports, we recently compared the in vitro activity of cefpiramide with those of several new broadspectrum P-lactam antibiotics against 921 All of the cephalosporins tested were considerably more active than cefpiramide against members of the family Enterobacteriaceae. The MICs of all five cephalosporins for 50 and 90% of the isolates (MIC50s and MIC90s, respectively) were similar and generally at least 16-fold lower than those of cefpiramide. The MICs of cefpiramide for P. aeruginosa were similar to those of piperacillin, ceftazidime, and cefoperazone and were lower than the reported MICs of the other 3-lactam antibiotics. The effect of inoculum size and testing medium on the susceptibility of P. aeruginosa to cefpiramide was also evaluated. An increase in inoculum from 104 to 106 CFU/ml resulted in a two-to fourfold increase in MIC. In addition, MICs obtained with MuellerHinton broth were equivalent to those obtained with tryptic soy broth but were twofold higher than those obtained with heart infusion broth.
The activities of all eight drugs against Pseudomonas spp. other than P. aeruginosa were highly variable. The activity of cefpiramide was equivalent to those of piperacillin, cefotaxime, and ceftriaxone and was lower than those of the other agents against these isolates. The activity of cefpiramide was equivalent to those of piperacillin and mezlocillin against isolates of Acinetobacter spp. and somewhat higher than those of the other ,-lactam antibiotics.
The findings in this study tend to support, in part, the findings reported previously in two large Japanese studies (1, 3) . As was noted by the previous investigators, cefpiramide had only moderate activity against members of the family Enterobacteriaceae compared with several other cephalosporins. In general, it was the least active cephalosporin against members of the family Enterobacteriaceae and was equivalent in activity to the ,B-lactam antibiotics piperacillin and mezlocillin.
The most interesting finding in the two previous studies isolates (77 strains) and blood culture isolates (60 strains) collected during the last 7 years. Thus, we believe that these isolates do not represent a resistant population of organisms currently present in our hospital population. Further studies from other hospitals will be necessary to define the in vitro activity of cefpiramide against P. aeruginosa.
One of the major problems with the use of broad-spectrum cephalosporins has been their marked lack of activity against enterococci, which can result in enterococcal superinfections (4) . The findings in our study and those of Fukasawa et al. (1) indicate that cefpiramide has good activity against enterococci ( Table 1 ). The MIC90s of cefpiramide were lower than those of any of the other cephalosporins tested and comparable to those of piperacillin and mezlocillin.
